FRCPath Haem Part 1 MCQ-Haemostasis 457
- amirhayat2527
- 2 minutes ago
- 1 min read
A 22-year-old woman has lifelong mucoccasions bleeding. Laboratory investigations show:
VWF antigen: 42 IU/dL
VWF activity: 18 IU/dL
VWF activity/VWF antigen ratio: 0.43
Multimer analysis: Loss of high-molecular-weight multimers
Ristocetin-induced platelet aggregation (RIPA): Increased at low-dose ristocetin
Platelet count: 105 × 10⁹/L
Which of the following is the most appropriate management regarding desmopressin (DDAVP)?
A. DDAVP is the treatment of choice because it increases VWF release from endothelial cells.
B. DDAVP is contraindicated because it may worsen thrombocytopenia by releasing abnormal VWF with increased platelet binding.
C. DDAVP should always be given before surgery in all patients with Type 2 VWD.
D. DDAVP has no effect on plasma VWF levels in Type 2B VWD.
E. DDAVP is indicated only if FVIII is below 30 IU/dL.